Involvement of Translation Initiation Factors in the Immune Response in the Elderly

Characterization of the Involvement of Translation Initiation Factors in the Immune Response to Acute Infection in the Elderly and Very Elderly

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01215604

Enrollment

Registered

2010-10-06

Start date

2010-10-31

Completion date

2012-10-31

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elderly Patient, Infection

Keywords

elderly patients, acute infection, translation initiation factors, eIF4E, eIF4G

Brief summary

The investigators propose that the translation initiation factors eIF4E and eIF4GI may be involved in resolution of acute inflammation (regardless of age). Furthermore, the investigators suggest that differences in translation initiation factors state of activation may contribute to inflammation. Finally, the investigators hypothesize that differences in translation initiation factors state of activation may underlie the immune compromised state of the very elderly affording additional explanation for the heightened morbidity from infection in this group. In the current study the investigators aim to test these hypotheses by measuring the levels of eIF4E and eIF4G, their regulators, and targets in elderly (65-84yrs) and very elderly (85yrs\<) patients hospitalized at Meir hospital for acute infection and after their recovery (detailed in study design).

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

65 Years to No maximum

Healthy volunteers

Inclusion criteria

* elderly patients (65\<) * hospitalized for acute infection (fever 38c\<, leukocytosis)

Exclusion criteria

* patients with dementia who can not sign informed consent of institutional Helsinki committee * patient with active cancer with active chemotherapy treatment

Countries

Israel

Outcome results